Abstract: Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.

Abstract: Systems and techniques relate to current slew control circuits. According to an aspect, a system implementing the quadratic slew control aspects comprises a disk; a read/write head; and a slew control circuit coupled to the read/write head, the slew control circuit configured to: receive an input current signal, apply a slew current to the input current signal in response to a change in a power setting for the read/write head, and provide an output current signal that is adjusted to a quadratic current slew based on the applied slew current, the output current signal generating an output voltage characterized by a linear slew and controlling a movement of the read/write head over the disk.

Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: A method for pre-amplifying an input voltage signal to a pre-amplified voltage signal. The method includes receiving the input voltage signal; obtaining a high-pass filtered voltage signal by applying a high-pass filter to the input voltage signal; processing the high-pass filtered voltage signal to a current signal that corresponds to the high-pass filtered voltage signal; transmitting the current signal through a differential transmission line; converting the transmitted current signal to a converted voltage signal that corresponds to the high-pass filtered voltage signal; and outputting the converted voltage signal as the pre-amplified voltage signal. An integrated circuit chip implementing the method is also disclosed.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: Power-on reset circuits and methods for providing a power-on reset signal are provided. A first branch is configured to receive the power supply voltage. The first branch comprises a first current generator configured to generate a first current having a positive relationship with a power supply voltage. A second branch receives the power supply voltage and comprises a second current generator that is configured to generate a second current. A relationship between the first and second currents indicates whether the power supply voltage exceeds a threshold voltage of the power-on reset circuit. A current comparator circuit compares the first current to the second current and generates an output based on the comparison. The power-on reset signal is asserted when the output indicates that the second current is greater than the first current.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: Compositions and methods are provided for measuring the amount of GAS6 in a sample. Also provided are compositions and methods related to high-affinity CAS6 inhibitor agents that induce a conformational change of GAS6 that stabilizes Helix A of GAS6.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Abstract: A system including transmission lines, read elements, and differential amplifiers. The read elements are connected in series. Each of the read elements is connected to a respective pair of the transmission lines. The differential amplifiers are connected respectively to the read elements via the transmission lines. The differential amplifiers are configured to amplify differential signals received from the respective pairs of the transmission lines.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: A system including a first transmission line, a second transmission line, a first element, a second element and a differential amplifier. The first element is configured to read a storage media to generate a read signal, where the first element is connected to the first transmission line. The second element is configured to detect interference and generate an interference signal, where the second element is connected to the second transmission line. The differential amplifier includes a first input and a second input, where the first input of the differential amplifier is connected to a the first transmission line and receives the read signal, and where the second input of the differential amplifier is connected to the second transmission line and receives the interference signal.

Abstract: A system including transmission lines, read elements, and differential amplifiers. The read elements are connected in series. Each of the read elements is connected to a respective pair of the transmission lines. The differential amplifiers are connected respectively to the read elements via the transmission lines. The differential amplifiers are configured to amplify differential signals received from the respective pairs of the transmission lines.

Abstract: A system including a first transmission line, a second transmission line, a first element, a second element and a differential amplifier. The first element is configured to read a storage media to generate a read signal, where the first element is connected to the first transmission line. The second element is configured to detect interference and generate an interference signal, where the second element is connected to the second transmission line. The differential amplifier includes a first input and a second input, where the first input of the differential amplifier is connected to a the first transmission line and receives the read signal, and where the second input of the differential amplifier is connected to the second transmission line and receives the interference signal.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.